For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on October 21st, 2025 | 07:20 CEST
SENSATION at DroneShield! Volatus Aerospace enters the AI era! thyssenkrupp rides the TKMS hype!
thyssenkrupp subsidiary TKMS celebrated an impressive stock market debut. On its first day of trading, the share price shot up by over 50%. Fittingly, German Defense Minister Pistorius emphasized investments in the navy during his visit to Atlantic NATO partners. Drone stocks Volatus Aerospace and DroneShield also rose sharply yesterday. The Australian company made headlines with revenue growth of over 1,000%. The outlook for Volatus is also bright – and its valuation remains more conservative.
Read
Commented by Fabian Lorenz on October 20th, 2025 | 07:15 CEST
Almost 150% upside potential! Plug Power, Bayer, Planethic Group
Is Planethic Group (formerly Veganz Group) offering the buying opportunity of the fall? Analysts see over 100% upside potential. The recent correction appears exaggerated and could be an attractive entry point. The Company itself reports massive demand. Plug Power shares have performed strongly in recent months. Instead of taking profits, analysts see further upside — although some voices remain cautious, as the Company has promised to reach break-even many times before. And what do analysts say about Bayer? Very little at the moment. Goldman Sachs recommends the stock as a "Buy", but there is potential for a setback with the upcoming Q3 figures.
Read
Commented by Fabian Lorenz on October 20th, 2025 | 07:00 CEST
BUYING OPPORTUNITY!? Gerresheimer crash! RENK correction! Nakiki shares following in the Bitcoin footsteps of Strategy and Metaplanet!
Nakiki SE is increasingly electrifying stock investors and the Bitcoin community. Following in the footsteps of Strategy, the Company aims to become the first German Bitcoin Treasury company in the regulated market. Around the initial Bitcoin purchases, Metaplanet and Capital B achieved price gains of over 100%. Could Nakiki follow suit? RENK shares are currently undergoing a correction. One analyst recently pointed out issues in the US business. Thursday could be an exciting day for RENK shareholders. Is it worth entering now? As for Gerresheimer, the stock appears unable to find a bottom. Analysts are far too slow in adjusting their price targets.
Read
Commented by Fabian Lorenz on October 17th, 2025 | 07:15 CEST
Acquisition of Vidac Pharma and Evotec? USD 400 billion at stake for Pfizer, Merck & Co!
Alarm bells are ringing in Big Pharma! Donald Trump appears serious about reducing drug prices. At the same time, patents on blockbuster drugs are expiring, threatening a USD 400 billion revenue shortfall. Pfizer, Merck, and Co. must refill their pipelines. The acquisition merry-go-round is expected to spin even faster in the coming years. Among the potential takeover targets is Vidac Pharma. The Company is still attractively priced, but if its new approach to fighting cancer proves successful in early clinical trials, a multiplication could be possible. And what about Evotec? The Hamburg-based company has repeatedly been traded as a takeover candidate in recent years. However, data and patents are offset by internal problems.
Read
Commented by Fabian Lorenz on October 16th, 2025 | 07:15 CEST
Hensoldt forges drone alliance! Nordex peaked? Over 10% dividend with RE Royalties
A dividend yield of over 10% currently makes RE Royalties shares an attractive buy. The Company finances renewable energy projects and will also participate in future earnings from these projects. With success, since 2020, the Company has grown by 38% p.a. and has paid dividends for 25 quarters. By comparison, Nordex is far from such continuity in growth. However, Nordex is currently riding a wave of growth. After a 100% increase in the share price, analysts see little potential for Nordex shares. Meanwhile, Hensoldt shares would likely have jumped after the latest announcement, as the sensor specialist is forging a new German drone alliance. Is now the time to buy?
Read
Commented by Fabian Lorenz on October 16th, 2025 | 07:05 CEST
Takeover fever and AI Opportunities: BioNTech, Novo Nordisk, PanGenomic Health
The pharmaceutical and biotech sector is buzzing with takeover activity. Following the announcement of a billion-dollar acquisition in the US, Novo Nordisk has announced its next deal, eyeing a potential best-in-class therapeutic for several rare diseases. Meanwhile, PanGenomic Health is positioning itself in the billion-dollar market for alternative medicine and dietary supplements, leveraging AI to provide added value to customers and capture market share. If successful, the stock could be significantly undervalued. BioNTech's acquisition of CureVac has now been completed, ending CureVac's period of suffering. In the process, BioNTech secures patents and elegantly resolves ongoing legal disputes.
Read
Commented by Fabian Lorenz on October 15th, 2025 | 08:35 CEST
BUYING OPPORTUNITY or Sell? Plug Power, Gerresheimer, AI insider tip NetraMark!
The stock markets are using the tariff dispute between the US and China as a reason for a correction. As a result, AI insider tip NetraMark has lost around 30% of its value in recent weeks. However, there is positive company news, and pressure from the US government on the biotech and pharmaceutical industry should generate additional interest in NetraMark's technology. So, is the correction a buying opportunity? And what about Plug Power? After the spectacular rise in the share price, the first analyst is already sounding a warning. Losses, and thus financing requirements, are likely to remain high. Gerresheimer's price targets are currently tumbling. Unfortunately, however, analysts are only just catching up with the stock's decline. Buy now or even sell?
Read
Commented by Fabian Lorenz on October 14th, 2025 | 07:30 CEST
Alternative to BioNTech, Evotec, and Co.: BioNxt Solutions impresses at investor conference and sparks takeover speculation
While the shares of BioNTech and Evotec are treading water, BioNxt Solutions is on an upward trajectory. The Company is currently shaking up Big Pharma. The announcement to replace the weight-loss injection Ozempic with an oral dissolvable film has sparked takeover speculation. BioNxt also aims to make waves in multiple sclerosis, another multi-billion-dollar market, by significantly simplifying the administration of a blockbuster drug for patients. At last week's IIF investor conference, the management board delivered a convincing presentation. Partnerships and licensing opportunities were outlined - assuming no acquisition occurs beforehand. This could prove highly rewarding for both a pharmaceutical company and shareholders.
Read
Commented by Fabian Lorenz on October 13th, 2025 | 07:30 CEST
Drone boom and multiplication: Following DroneShield, RENK, and Standard Lithium, NEO Battery Materials shares are taking off!
Missed out on the multiplication of shares such as DroneShield, RENK, and Standard Lithium? Investors can still get in early with NEO Battery Materials. The Company is benefiting from the drone boom and the raw materials conflict between the US and China. NEO Battery Materials has developed advanced battery technology. The first manufacturer of drone batteries has already placed an order. In the future, the Company also plans to offer complete batteries itself. To save time in commercialization, a factory has been leased. This will allow for rapidly increasing sales and profits. The tariff and raw materials conflict between the US and China is likely to give NEO an additional boost. When will the stock take off?
Read
Commented by Fabian Lorenz on October 13th, 2025 | 07:05 CEST
Winners in the tariff war: Almonty Industries, MP Materials, Bayer
Stock market turmoil on Friday: Donald Trump once again threatens to wield the tariff club. This came in response to China's announcement to tighten export controls on rare earths. Yet, there are also winners in the raw materials battle between the two superpowers. In recent months, the US government has invested in companies such as MP Materials, focusing so far on rare earths and lithium. Will tungsten be next? This critical metal has not been mined in the US for a long time, and Almonty would be the logical partner to change that. Notably, while US stocks lost ground, in some cases heavily, on Friday, Almonty shares recovered significantly from their intraday lows.
Read